Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: A multicenter randomized controlled trial

S. H. Lee, H. K. Park, W. S. Ryu, J. S. Lee, H. J. Bae, M. K. Han, Y. S. Lee, H. M. Kwon, Chi Kyung Kim, E. S. Park, J. W. Chung, K. H. Jung, J. K. Roh

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and purpose: We investigated the effect of celecoxib, a selective inhibitor of cyclo-oxygenase 2, in patients with intracerebral hemorrhage (ICH). Methods: We conducted a multicenter, randomized, controlled, and open with blinded end-point trial of 44 Korean patients 18years or older with ICH within 24h of onset. The intervention group (n=20) received celecoxib (400mg twice a day) for 14days. The control group (n=24) received the standard medical treatment for ICH. The primary end-point was the number of patients with a change in the volume of perihematomal edema (PHE) from the 1st to the 7th±1day (cut-off value, 20%). Results: The time from onset to computed tomography scan slightly differed between groups (177±160min for control vs. 297±305min for the celecoxib group; P=0.10). In the primary end-point analysis using cut-off values, there was a significant shift to reduced expansion of PHE in the celecoxib group (P=0.005). With respect to the secondary end-points, there was also a significant shift to reduced expansion of ICH in the celecoxib group (P=0.046). In addition, the expansion rate of PHE at follow-up tended to be higher in the control group than in the celecoxib group (90.6±91.7% vs. 44.4±64.9%; P=0.058). Conclusions: In our small, pilot trial, administration of celecoxib in the acute stage of ICH was associated with a smaller expansion of PHE than that observed in controls.

Original languageEnglish
Pages (from-to)1161-1169
Number of pages9
JournalEuropean Journal of Neurology
Volume20
Issue number8
DOIs
Publication statusPublished - 2013 Aug 1
Externally publishedYes

Fingerprint

Celecoxib
Cerebral Hemorrhage
Hematoma
Edema
Randomized Controlled Trials
Control Groups
Cyclooxygenase Inhibitors

Keywords

  • Brain edema
  • Celecoxib
  • Clinical trial
  • Intracerebral hemorrhage

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage : A multicenter randomized controlled trial. / Lee, S. H.; Park, H. K.; Ryu, W. S.; Lee, J. S.; Bae, H. J.; Han, M. K.; Lee, Y. S.; Kwon, H. M.; Kim, Chi Kyung; Park, E. S.; Chung, J. W.; Jung, K. H.; Roh, J. K.

In: European Journal of Neurology, Vol. 20, No. 8, 01.08.2013, p. 1161-1169.

Research output: Contribution to journalArticle

Lee, SH, Park, HK, Ryu, WS, Lee, JS, Bae, HJ, Han, MK, Lee, YS, Kwon, HM, Kim, CK, Park, ES, Chung, JW, Jung, KH & Roh, JK 2013, 'Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: A multicenter randomized controlled trial', European Journal of Neurology, vol. 20, no. 8, pp. 1161-1169. https://doi.org/10.1111/ene.12140
Lee, S. H. ; Park, H. K. ; Ryu, W. S. ; Lee, J. S. ; Bae, H. J. ; Han, M. K. ; Lee, Y. S. ; Kwon, H. M. ; Kim, Chi Kyung ; Park, E. S. ; Chung, J. W. ; Jung, K. H. ; Roh, J. K. / Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage : A multicenter randomized controlled trial. In: European Journal of Neurology. 2013 ; Vol. 20, No. 8. pp. 1161-1169.
@article{23a5ad94350244f4bea289c28298bbb4,
title = "Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: A multicenter randomized controlled trial",
abstract = "Background and purpose: We investigated the effect of celecoxib, a selective inhibitor of cyclo-oxygenase 2, in patients with intracerebral hemorrhage (ICH). Methods: We conducted a multicenter, randomized, controlled, and open with blinded end-point trial of 44 Korean patients 18years or older with ICH within 24h of onset. The intervention group (n=20) received celecoxib (400mg twice a day) for 14days. The control group (n=24) received the standard medical treatment for ICH. The primary end-point was the number of patients with a change in the volume of perihematomal edema (PHE) from the 1st to the 7th±1day (cut-off value, 20{\%}). Results: The time from onset to computed tomography scan slightly differed between groups (177±160min for control vs. 297±305min for the celecoxib group; P=0.10). In the primary end-point analysis using cut-off values, there was a significant shift to reduced expansion of PHE in the celecoxib group (P=0.005). With respect to the secondary end-points, there was also a significant shift to reduced expansion of ICH in the celecoxib group (P=0.046). In addition, the expansion rate of PHE at follow-up tended to be higher in the control group than in the celecoxib group (90.6±91.7{\%} vs. 44.4±64.9{\%}; P=0.058). Conclusions: In our small, pilot trial, administration of celecoxib in the acute stage of ICH was associated with a smaller expansion of PHE than that observed in controls.",
keywords = "Brain edema, Celecoxib, Clinical trial, Intracerebral hemorrhage",
author = "Lee, {S. H.} and Park, {H. K.} and Ryu, {W. S.} and Lee, {J. S.} and Bae, {H. J.} and Han, {M. K.} and Lee, {Y. S.} and Kwon, {H. M.} and Kim, {Chi Kyung} and Park, {E. S.} and Chung, {J. W.} and Jung, {K. H.} and Roh, {J. K.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1111/ene.12140",
language = "English",
volume = "20",
pages = "1161--1169",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage

T2 - A multicenter randomized controlled trial

AU - Lee, S. H.

AU - Park, H. K.

AU - Ryu, W. S.

AU - Lee, J. S.

AU - Bae, H. J.

AU - Han, M. K.

AU - Lee, Y. S.

AU - Kwon, H. M.

AU - Kim, Chi Kyung

AU - Park, E. S.

AU - Chung, J. W.

AU - Jung, K. H.

AU - Roh, J. K.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background and purpose: We investigated the effect of celecoxib, a selective inhibitor of cyclo-oxygenase 2, in patients with intracerebral hemorrhage (ICH). Methods: We conducted a multicenter, randomized, controlled, and open with blinded end-point trial of 44 Korean patients 18years or older with ICH within 24h of onset. The intervention group (n=20) received celecoxib (400mg twice a day) for 14days. The control group (n=24) received the standard medical treatment for ICH. The primary end-point was the number of patients with a change in the volume of perihematomal edema (PHE) from the 1st to the 7th±1day (cut-off value, 20%). Results: The time from onset to computed tomography scan slightly differed between groups (177±160min for control vs. 297±305min for the celecoxib group; P=0.10). In the primary end-point analysis using cut-off values, there was a significant shift to reduced expansion of PHE in the celecoxib group (P=0.005). With respect to the secondary end-points, there was also a significant shift to reduced expansion of ICH in the celecoxib group (P=0.046). In addition, the expansion rate of PHE at follow-up tended to be higher in the control group than in the celecoxib group (90.6±91.7% vs. 44.4±64.9%; P=0.058). Conclusions: In our small, pilot trial, administration of celecoxib in the acute stage of ICH was associated with a smaller expansion of PHE than that observed in controls.

AB - Background and purpose: We investigated the effect of celecoxib, a selective inhibitor of cyclo-oxygenase 2, in patients with intracerebral hemorrhage (ICH). Methods: We conducted a multicenter, randomized, controlled, and open with blinded end-point trial of 44 Korean patients 18years or older with ICH within 24h of onset. The intervention group (n=20) received celecoxib (400mg twice a day) for 14days. The control group (n=24) received the standard medical treatment for ICH. The primary end-point was the number of patients with a change in the volume of perihematomal edema (PHE) from the 1st to the 7th±1day (cut-off value, 20%). Results: The time from onset to computed tomography scan slightly differed between groups (177±160min for control vs. 297±305min for the celecoxib group; P=0.10). In the primary end-point analysis using cut-off values, there was a significant shift to reduced expansion of PHE in the celecoxib group (P=0.005). With respect to the secondary end-points, there was also a significant shift to reduced expansion of ICH in the celecoxib group (P=0.046). In addition, the expansion rate of PHE at follow-up tended to be higher in the control group than in the celecoxib group (90.6±91.7% vs. 44.4±64.9%; P=0.058). Conclusions: In our small, pilot trial, administration of celecoxib in the acute stage of ICH was associated with a smaller expansion of PHE than that observed in controls.

KW - Brain edema

KW - Celecoxib

KW - Clinical trial

KW - Intracerebral hemorrhage

UR - http://www.scopus.com/inward/record.url?scp=84880135647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880135647&partnerID=8YFLogxK

U2 - 10.1111/ene.12140

DO - 10.1111/ene.12140

M3 - Article

C2 - 23551657

AN - SCOPUS:84880135647

VL - 20

SP - 1161

EP - 1169

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 8

ER -